Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 41

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 41
---

of much debate and litigation throughout the world. In addition, the laws of foreign countries may not protect our rights to the same
extent as the laws of the United States, or vice versa. The standards that the United States Patent and Trademark Office (the “USPTO”)
(and foreign countries) use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform,
worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. Accordingly,
we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents
issued to us or to others. The issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain.
The subject matter claimed in a patent application can be significantly reduced or eliminated before the patent issues, if at all, and
its scope can be reinterpreted or narrowed after issuance. Therefore, our pending and future patent applications may not result in patents
being issued in relevant jurisdictions that protect our drug candidates, in whole or in part, or that effectively prevent others from
commercializing competitive drug candidates, and even if our patent applications issue as patents in relevant jurisdictions, they may
not issue in a form that will provide us with any meaningful protection for our drug candidates or technology, prevent competitors from
competing with us or otherwise provide us with any competitive advantage. Additionally, our competitors may be able to circumvent our
patents by challenging their validity or by developing similar or alternative drug candidates or technologies in a non-infringing manner.

The issuance of a patent is not conclusive as
to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United
States and abroad. We may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in opposition,
derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or
the patent rights of others, or other proceedings in the USPTO or applicable foreign offices that challenge priority of invention or other
features of patentability. An adverse determination in any such submission, proceeding or litigation could result in loss of exclusivity
or ability to sell our products free from infringing the patents of third parties, patent claims being narrowed, invalidated or held unenforceable,
in whole or in part, and limitation